India-UK FTA Secures Generic Drug Industry

The India-UK free trade agreement (FTA) will not require patent term extensions or data exclusivity, protecting India's domestic generic drug industry. This FTA, crucial for the pharmaceutical sector, rejects demands for data exclusivity, allowing generic manufacturers to commercially operate post-patent expiration without delay.

The recently signed India-UK free trade agreement (FTA) provides significant protections for India's domestic generic drug industry, as it does not mandate patent term extensions or data exclusivity, according to a commerce ministry document.

The agreement counters the UK's demands for 'data exclusivity' provisions by ensuring India's patent law provisions remain robust, safeguarding the sector's interests.

This move secures the operations of India's USD 25-billion generic drug industry by allowing manufacturers to enter the market swiftly upon patent expiration, in the absence of patent linkage or automatic injunctions.